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ABSTRACT 
Objective: An accurate, simple, and rapid HPLC-UV based method for the quantitative determination of ritonavir (RTV) in human plasma is 
developed.  
Methods: The method involved deproteinization of the sample with 0.125N NaOH and methyl tertiary butyl ether and evaporated to dryness. The 
residue was reconstituted with mobile phase (20 mM Sodium Acetate and Acetonitrile–55:45 v/v). The analysis was done using C8 column (250 x 
4.6 mm ID) and detection at a wavelength of 212 nm 
Results: The method range was linear over the range 0.5–10.0 µg/ml as derived using calibration curve method. Mean intra-and inter-day variations 
over the ranges of the standard curves were less than 10 % and mean extraction recoveries from human plasma ranged from 96 to 110 %.  
Conclusion: A rapid and accurate method for quantitation of RTV in plasma was validated. The assay spans the concentration range of clinical 
interest. The easy sample preparation and small sample size makes this assay highly suitable for pharmacokinetic studies of RTV in HIV-infected 
patients with TB.  
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INTRODUCTION 
The clinical treatment of patients with human immunodeficiency 
virus (HIV-1) infection has been advanced by the development of 
highly active antiretroviral therapy (HAART). However, some 
patients develop drug resistance and metabolic complications. This 
undesirable outcome may result from a failure to achieve effective 
antiretroviral drug plasma concentrations.  
Therefore monitoring plasma drug concentrations is essential to 
ensure optimal drug efficacy, to prevent viral resistance, to 
manage drug interactions, to avoid adverse effects, and to assess 
non adherence [1-2]. Ritonavir (RTV), is an antiretroviral 
medication along with other medications to treat HIV/AIDS. 
Ritonavir, originally developed as an inhibitor of HIV protease, is 
widely used as a booster for other protease inhibitors. 
Additionally, because RTV is metabolized by cytochrome P450 
enzymes, monitoring may be useful for evaluation of drug-drug 
interactions, such as those with a potent CYP 3A4 inducer or 
inhibitor that has been shown to increase or decrease the RTV 
plasma concentration. 
In recent years, several HPLC methods for simultaneous 
determination of anti-retroviral drugs in plasma have been 
published [3-23]. Most of the methods using HPLC, though they are 
reliable and sensitive, have some critical disadvantages involving 
solid phase extraction, special columns, gradient elution programs, 
cumbersome operation procedures, larger sample volumes, multiple 
wavelengths, special detectors and/or longer run time. Other 
methods for quantification of antiretroviral drugs by tandem mass 
spectrometry (LCMS/MS) [24-29] and matrix-assisted laser 
desorption/ionization-triple quadrapole tandem mass spectrometry 
(MALDI-QqQ-MS/MS) [30, 31] have also been published and these 
sophisticated equipments may not be available in conventional 
hospital laboratories and also requires high analytical cost. 
Therefore we aimed to develop a simple, economical and reliable 
chromatographic method for the determination of ritonavir (RTV) in 
plasma using lopinavir (LPV) as internal standard.  
MATERIALS AND METHODS 
Chemicals and reagents 
RTV (Code No: RD322) and LPV (Code No: R8FB6) were kindly 
provided by Cipla Ltd. Acetonitrile used was of HPLC grade (Merck, 
India). Sodium Acetate, methyl tert butyl Ether and Sodium 
hydroxide from Qualigens (India) were used. Deionized water was 
processed through a Milli-Q water purification system (Millipore, 
USA). Pooled human plasma from healthy volunteers was obtained 
from Lions Blood Bank, Chennai, India. 
Chromatographic system  
The HPLC system (Shimadzu Corporation, Kyoto, Japan) consisted of 
two pumps (LC-10ATvp), diode array detector (SPD-M10Avp) and 
autosampler with built-in system controller (SIL-HTA). ClassVP-LC 
workstation was used for data collection and acquisition. The 
analytical column was a C8, 250 x 4.6 mm ID, 5 µm particle size 
(Lichrospher 100 RP-8e, Merck, Germany) protected by a 
compatible guard column.  
Chromatographic conditions 
The mobile phase consisted of 20 mM Sodium Acetate in water, pH 4.8 
(adjusted with 1N HCl) and acetonitrile (55:45 v/v). Prior to 
preparation of the mobile phase, the aqueous Sodium acetate and 
acetonitrile were degassed separately using a Millipore vacuum pump 
and filtered through 0.4 µm nylon membrane filter. The UV detector 
was set at a wavelength of 212 nm. The chromatogram was run for 13 
min at a flow rate of 1.5 ml/min at ambient temperature. Unknown 
concentrations were derived from linear regression analysis of the 
peak height ratios (analyte/internal standard) vs. Concentration curve. 
The linearity was verified using estimates of coefficient of 
determinants (r) and correlation coefficient (R2) values. 
Preparation of standard solution  
A stock standard (1 mg/ml) was prepared by dissolving RTV in 
methanol. The working standards of RTV in concentrations ranging 
from 0.5 to 10.0µg/ml were prepared in human plasma. 
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Sample preparation  
To 200 µl each of calibration standards and test samples, 20 µl of 
LPV (internal standard) was added at a concentration of 100µg/ml. 
This was mixed with 400 µl of 0.125N NaOH and 2.0 ml of methyl 
tertiary butyl ether, the contents were vortexed vigorously, and 
centrifuged at 5,000 rpm for 5 min. 1.5 ml of the clear supernatant 
was taken into the test tube, evaporated to dryness in a nitrogen 
evaporator (Turbo vap) for 20 min. The dried residue was 
reconstituted in 100 µl of mobile phase; 75 µl was injected into the 
HPLC column. 
Accuracy and linearity  
The accuracy and linearity of RTV standards were evaluated by 
analyzing a set of standards ranging from 0.5 to 10.0µg/ml. The 
within day and between day variations were determined by 
processing each standard concentration in duplicate for six 
consecutive days. 
Precision  
In order to evaluate the precision of the method, patient samples at 
three different concentrations of RTV (0.73, 1.15 and 3.34 µg/ml) 
were analysed in duplicate on three consecutive days. 
Recovery  
Varying concentrations of RTV (1.5, 3.5, and 7.5 µg/ml) were prepared 
in drug-free human plasma and extracted as described above along 
with the internal standard. The percentage of the drug recovered from 
the plasma samples was determined by comparing the peak height 
ratio after extraction with those of unextracted methanolic solutions 
containing same concentrations of RTV as in plasma. Recovery 
experiments were carried out on three different occasions. 
Specificity 
Co elution from endogenous compound was investigated by 
analysing blank plasma samples obtained from six each of male and 
female subjects. Interference from certain antiretroviral drugs, 
namely, nevirapine, efavirenz, zidovudine, tenofovir, didanosine, 
stavudine, lamivudine, lopinavir, indinavir and saquinavir at a 
concentration of 10µg/ml and anti-tuberculosis drugs such as, 
isoniazid, pyrazinamide, rifampicin, ethambutol, streptomycin was 
also evaluated. 
Limit of detection (LOD) and lower limit of quantitation (LLOQ) 
The (LOD) and (LLOQ) were calculated using slope analysis of 0.5–
20 ng/ml for RTV using the formula LOD= 3 x S. D/Slope and LOQ = 
10 x S. D/slope. 
Pharmacokinetic application of methods to human plasma 
samples 
Serial blood samples at pre-dosing (0 hour) and at 1, 2, 4, 6, 8 and 12 h 
post dosing were drawn in heparinized containers from six HIV-
infected adult patients with tuberculosis who were receiving ritonavir 
(100 mg daily) as part of the treatment regimen.  
All the blood samples were centrifuged and plasma was separated and 
stored at-20oC until assay. Estimation of plasma RTV was undertaken 
within 24 to 48 h of blood collection. Informed written consent was 
obtained from the parent before blood draws were made.  
RESULTS AND DISCUSSION 
Method development 
The analytical method developed was based on the protocol set out 
in the International Conference on Harmonization (ICH) guidelines 
[32]. Under the chromatographic conditions described above, peaks 
of RTV was presented in separate retention time with other elutants 
as seen in the chromatograms representing high and low 
concentrations (fig. 1a, b). The retention times of RTV and the 
internal standard (LPV) were 10.0 and 11.4 min respectively. Blank 
plasma samples did not give any peak at the retention times of RTV 
(fig. 1c).  
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Fig. 1: (a) Chromatogram of extracted RTV plasma standard 
10.0 µg/ml (contains 20 µl of LPV added at the concentration of 
100 µg/ml); (b) Chromatogram of extracted RTV plasma 
standard 0.5 µg/ml (contains 20 µl of LPV added at the 
concentration of 100 µg/ml); (c) Chromatogram of extracted 
blank plasma (contains 20 µl of LPV added at the concentration 
of 100 µg/ml) 
 
No endogenous substances or antiretroviral drugs such as 
nevirapine, efavirenz, zidovudine, tenofovir, didanosine, stavudine, 
lamivudine, lopinavir, indinavir and saquinavir or first-line anti-
tuberculosis drugs such as isoniazid, pyrazinamide, ethambutol and 
streptomycin was coeluted as cross checked using pure standards 
with the RTV chromatogram.  
Ritonavir concentrations ranging from 0.5-10.0 µg/ml were checked 
for linearity. The calibration curve parameters of RTV from six 
individual experiments for standard concentrations ranging from 0.5 
to 10.0µg/ml showed a linear relationship between peak height ratio 
and concentrations. The mean (+SD) correlation coefficient, slope 
and intercept values were 0.9997, 0.266 and-0.0232 respectively. 
The linearity and reproducibility of the various standards used for 
constructing calibration graphs for plasma RTV are shown in fig. 2. 
The within-day and between-day percent variation (CV) for 
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standards containing 0.5 to 10.0µg/ml ranged from 3.4 to 7.9% and 
2.0 to 10.3% respectively (table 1). 
 
Calibration curve for RTV 




















Fig. 2: Linear response of spiked plasma RTV concentrations 
ranging from 0.5–10.0 µg/ml 
 
Table 1: Linearity and reproducibility of plasma RTV standards 
S. 
No. 
 Mean peak height ratio±SD (RSD %) 
Concentrations 
(µg/ml) 
Intraday (n=6) Inter day (n=6) 
1 10.0 2.747±0.055(2.0) 2.650±0.090(3.4) 
2 5.0 1.267±0.032 (2.5) 1.287±0.095 
(7.4) 
3 2.5 0.620±0.026 (4.2) 0.623±0.027 
(4.3) 




5 0.5 0.117±0.012 
(10.3) 
0.127±0.010(7.9) 
Data given is the mean of 6 samples±Standard deviation and 
Relative Standard deviation in the parantheses, 
Table 2: Precision of plasma RTV assay 
S. No. mean±SD 
Sample 1 0.72±0.04 
Sample 2 1.17±0.04 
Sample 3 3.21±0.10 
The values given are the mean of 3 concentrations with standard 
deviation 
The reproducibility of the method was further evaluated by 
analyzing three plasma samples containing different concentrations 
of RTV. The RSD for these samples ranged from 2.6 to 5.0% (table 2). 
The % variations from the actual concentrations ranged from 92 to 
104%. (LOD) and lower (LLOQ) were 140 ng/ml and 0.4 ug/ml 
respectively. The percent recovery of RTV from plasma ranged from 
98 to 108% (table 3). The mean concentrations of RTV in serial 
blood samples collected at predosing (0 hour) and at 1, 2, 4, 6, 8, 12 
and 24 h post dosing were 0.17, 0.63, 1.38, 1.60, 1.22, 0.91, 0.40 and 
0.09 µg/ml respectively (fig. 3). 
 


























Fig. 3: RTV concentrations in HIV-TB patients. The above values 
are mean plasma concentrations of RTV obtained from 6 
patients who were administered oral dose of 100 mg of RTV 
 
Table 3: Recovery 
S. No. Base Added (µg/ml) Actual (µg/ml) Obtained (µg/ml) Recovery (%) 
1 1.0 0.5 1.5 1.59 106 
2 1.0 2.5 3.5 3.85 110 
3 5.0 2.5 7.5 7.24 96 
 
DISCUSSION 
LPV/RTV is a major antiretroviral in salvage regimens, has been 
proven effective in Chinese HIV-positive adults with first-line 
treatment failure [33-35]. Thus, the establishment of a quantitative 
method for determination of RTV in clinical pharmacokinetic studies 
and therapeutic drug monitoring is necessary.  
There have been recent reports of HPLC methods for the 
simultaneous determination of antiretroviral drugs which includes 
RTV. However, these methods have several disadvantages in terms 
of cost performance [24-29], time consumption [4–20], necessary 
equipments [30, 31], the use of expensive disposable solid phase 
extraction cartridges [8] and gradient elution control.  
We describe the development, validation and application of a simple 
HPLC method for quantitative determination of RTV in human 
plasma using LPV as internal standard. The principal advantages of 
our method are a rapid liquid-liquid drug extraction from plasma in 
a simple one-step sample preparation and using a small sample 
volume (200 microlitres) without any loss of analyte, an isocratic 
elution on a reversed phase C8 column and a shorter run time when 
compared to the existing methods.  
The developed method was simple, specific and did not require any 
expensive equipment or extra processing steps. A gradient elution 
program is commonly used for determination of LPV and RTV [36-
38]. However, this requires binary pump system, a difficult elution 
procedure, long run time and results in consumption of large volume 
of reagent. Under isocratic conditions, as described here, the run 
time was short (13 min) and there was no need for the analytical 
column to be washed or re-equilibrated between runs. This 
condition provided good resolutions for the analyte peaks and 
separated them from endogenous interferences in plasma and 
companion antiretroviral drugs.  
The method was quite robust as evidenced by a discrete peak 
denoting RTV. The percent variations (within-day and between-day) 
for the standards were below 10%. The method reliably yielded an 
acceptable range of recovery. Further, data from the accuracy and 
precision experiments yielded satisfactory results.  
In view of its potent anti-retroviral activity, RTV is used in the 
treatment regimen along with other anti-retroviral and anti-
tuberculosis drugs in HIV positive patients with and without 
tuberculosis, who fail to first-line anti-retroviral drugs. It therefore 
becomes necessary to rule out interference of both these classes of 
drugs in the assay of RTV and establish the specificity of the method. 
The method was highly specific for RTV; drugs such as nevirapine, 
efavirenz, zidovudine, tenofovir, didanosine, stavudine, lamivudine, 
lopinavir, indinavir and saquinavir or anti-tuberculosis drugs such 
as rifampicin, isoniazid, pyrazinamide, ethambutol, streptomycin or 
any endogenous substance interfered in the assay. 
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When this method was applied to estimate RTV in plasma samples 
collected serially at different time points from adult HIV-TB patients 
who received 100 mg of RTV along with LPV and other anti-
tuberculosis and second line anti-retroviral drugs, we obtained a 
mean peak concentration of 1.59 µg/ml, which was within the 
therapeutic range of RTV (9).  
Thus the method spans the range of clinical interest and could be 
applied to pharmacokinetic studies in both adults and children. Most 
of the methods published were simultaneous determination of anti-
retroviral drugs which requires longer run time and permits 
quantitation of limited samples. The method has the potential to 
implement at low budget hospital environment, as it does not 
require high operational cost instruments such as NMR or tandem 
mass spectrometers. 
CONCLUSION 
A sensitive, specific and validated method for quantitative 
determination of RTV in plasma is described. This simple, rapid, 
accurate and reproducible method utilizes a single step direct 
extraction without involvement of expensive solid phase cartridges. 
The chromatogram yields a well-resolved peak for RTV with good 
intra-and inter-day precision. This simple HPLC method can be 
conveniently used as a routine clinical application and enables study 
of the drug pharmacokinetics in conventional hospital and research 
laboratories. 
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